#13 How to talk about risks – Alexandra Freeman
Listen now
Description
People’s perception of risk can vary greatly from person to person, making it challenging for healthcare professionals to communicate benefits and harms of medicines in a balanced fashion. Alexandra Freeman from the Winton Centre for Risk and Evidence Communication discusses how to give patients the information they need to decide what's best for them. Tune in to find out: Why people perceive risks so differentlyWhy medical communicators should strive to inform rather than persuadeHow to communicate in a trustworthy fashion Want to know more? There is no right way to communicate evidence to patients, but there are a few things you can do to avoid getting it wrong.Conventional communication techniques are good for persuading people – but when the aim is to inform, the principles of evidence communication should be applied instead.Graphics can help people translate abstract numbers into contextualised risks they can relate to, like these visuals that illustrate the risk of blood clots with the AstraZeneca COVID-19 vaccine.These evidence-based guidelines can help professional communicators illustrate the personalised risk of dying from COVID-19.The Winton Centre offers plenty of resources on risk and evidence communication, including free e-learning courses for healthcare professionals, the Risky Talk podcast with statistician David Spiegelhalter, and the RealRisk tool to help healthcare professionals and communicators extract the right statistics from academic papers.For more on communicating benefits and harms in pharmacovigilance, revisit this Drug Safety Matters episode on vaccine safety communication. Join the conversation on social media Follow us on Twitter, Facebook or LinkedIn and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.
More Episodes
Serious and unexpected adverse drug reactions – the ‘black swans’ of pharmacovigilance – can place enormous strain on safety monitoring systems. Drawing examples from the COVID-19 pandemic, François Montastruc from Toulouse University Hospital explains how we can get better at dealing with the...
Published 02/29/24
Published 02/29/24
The liver is the primary site for drug metabolism in the body, but it can be severely damaged by medicines or their toxic compounds. Rita Baião from the North Lisbon University Hospital Center reviews what pharmacovigilance professionals should know about drug-induced liver injury (DILI). Tune...
Published 02/01/24